Review Article

INTERNATIONAL JOURNAL OF EXPERIMENTAL AND BIOMEDICAL RESEARCH

Published by PharmaSprings Publication Journal Home Page: https://pharmasprings.com/ijebr

Analysis of Regulatory Strategies for Generic Product Approval across Asian Nations

A.Rajyalakshmi[1], Gayathri V[2], Audinarayana Nelavala[1]*

[1]Department of Pharmaceutics, Sri Venkateswara College of Pharmacy (Autonomous), RV Nagar, Tirupathi Road, Chittoor-517127, Andhra Pradesh, India

[2]Sri Venkateswara College of Pharmacy (Autonomous), RV Nagar, Tirupathi Road, Chittoor-517127, Andhra Pradesh, India

Article History:

Received on: 26 Oct 2023
Revised on: 01 Nov 2023
Accepted on: 02 Nov 2023

Keywords:

Regulatory strategies, Healthcare affordability, Market access, Bioequivalence, Legal framework

Abstract

The pharmaceutical industry is critical for providing accessible, affordable healthcare globally. This study compares regulatory strategies for generic drug approvals in Europe and Asia, focusing on India, China, and Japan. It analyzes legal frameworks, evaluation criteria, data requirements, and approval timelines, aiming to understand the impact on the efficiency of generic drug market entries in these regions. The research methodology includes reviewing regulatory guidelines, legislative documents, scholarly publications, and conducting interviews and surveys with industry experts. Preliminary findings reveal significant differences in the legal and procedural requirements across Asian nations, with variations in the emphasis on local clinical data and approval timelines. These disparities affect market accessibility, competition, and healthcare affordability. Insights from this study are vital for pharmaceutical companies navigating international markets and for policymakers aiming to harmonize and expedite approval processes, ultimately improving global access to cost-effective healthcare solutions.

*Corresponding Author

Name: N.Audi Narayana
Phone: +91 81068 36131
Email: audinarayana@svcop.in

eISSN: 2583-5254
DOI: https://doi.org/10.26452/ijebr.v3i1.557

Production and hosted by
Pharmasprings.com

INTRODUCTION

Aspects of Pharmaceutical Products Regulation

Since pharmaceuticals and medicines directly affect the public's health and quality of life, we are unable to classify them as common or general goods. Highest level of technical and non-technical knowledge is a prerequisite for control as well as evaluation of such items because the severity of pharmaceutical products should be taken into account at every stage [1]. The combination of legal, administrative, and technological measures used by governments to ensure the quality, safety, and efficacy of drugs as well as the relevance and

accuracy of product information is known as pharmaceutical regulation [2].

The pharmaceutical sector, which supplies millions of people with necessary pharmaceuticals, is a pillar of global healthcare. Generic pharmaceutical products, which provide affordable substitutes for name-brand medications, are essential for ensuring healthcare access and affordability globally [3]. However, there are considerable regional differences in the regulatory framework for generic medicine clearance, notably amongst Asian countries. Particularly in economically varied regions like Europe and Asia, generic pharmaceuticals are crucial for lowering healthcare costs and increasing access to life-saving medications [4]. The regulatory approaches that led to its approval must be understood if healthcare systems are to be optimized [5].

Asian countries, such as India, China, and Japan, have various and frequently independent regulatory regimes, which operate under a centralized regulatory framework overseen by the Agency). Market accessibility is directly impacted by the effectiveness and timeliness of generic product approval. The supply of important pharmaceuticals may be delayed or cost more due to ineffective approval procedures [6][7][8]. It is possible to standardize and harmonize approval procedures by understanding the differences in regulatory approaches. This might increase effectiveness, cut down on redundant work, and ultimately benefit patients and the industry. Understanding the regulatory intricacies in various locations is essential for pharmaceutical businesses' strategic planning, which includes resource allocation, product launch timing, and market entry tactics [9][10].

Objectives of Regulatory Strategies for Generic Product Approval across Asian Nations

- Examine the legal systems of important Asian countries like China, Japan, and India.
- Examine the evaluation criteria that are utilized in European regulatory systems to determine the bioequivalence and safety of generic medications. Compare the evaluation standards used by Asian countries to approve generic products [11].
- Assess the data requirements, such as those for clinical trial results, pharmacokinetic studies, and stability data, for the approval of generic products in Europe. Compare the data specifications set forth by Asian regulatory bodies [12].
- To Assess Approval Timelines: Examine the timetables related to the European Union's approval procedure for generic products, from submission to market entry. While taking into account variances in review and decision-making processes, compare the approval times in important Asian countries [13].
- To Research Post-Market monitoring: Look at the pharmacovigilance procedures and post-market monitoring programs in place for generic drugs in both the European and Asian areas [14].
- To determine the factors that affect how quickly generic products are approved in Europe and Asia, including the legal, technical, and procedural elements, identify and analyse these factors [15].
- To obtain stakeholder perspectives, conduct surveys and interviews with regulatory experts, business leaders, and stakeholders to gain qualitative understanding of the benefits and drawbacks of regional regulatory frameworks [16].
- To Assess Market Accessibility and Competition Dynamics: Assess the effects of regulatory policies on the availability of the market for generic drugs and the dynamics of competition in the pharmaceutical sector in both the European and Asian markets.
- To offer Policy Recommendations: Based on the findings, suggest policies that will promote harmonization, streamline approval procedures, and improve worldwide access to affordable healthcare options [17].

- To add to the Body of Knowledge in Pharmaceutical Regulatory Affairs: Add to the body of knowledge in pharmaceutical regulatory affairs by offering a thorough comparative analysis of generic product approval procedures in European and Asian countries [18].

Regulatory Strategies for Generic Product Approval across Asian Nations

The Association of Southeast Asian Nations (ASEAN) works to advance regional harmony and peace, encourage cooperation and mutual aid among its member states, and quicken regional development in terms of its economy, society, and culture [19]. In order to achieve this goal, member nations are working to create harmonised standards that will help to remove technical trade barriers and ease the creation of an integrated market. The healthcare sector is one of the main ones taken into account for economic integration. ASEAN leaders decided to create a single production base and a single market across all of the ASEAN nations. Pharmaceutical products are one of the key components of this vision among all the products because of their social and economic ramifications [20][21][22][23].

In addition, the main focus of the ASEAN leaders was on the importance of immediate access to the required pharmaceutical supplies in order to give relief in the event of a public health emergency [24]. By taking this into account, ASEAN collaboration for the start of medication and vaccine security as well as self-Reliance comes together. For ASEAN nations, the removal of technical trade obstacles was essential, which is why in 2009, ASEAN's economic ministers gathered to adopt the Asian Trade in Goods Agreement. The ASEAN Consultative Committee for Standards and Quality (ACCSQ) was designated to oversee the establishment of a Single Production Base and Single Market for Pharmaceuticals in the ASEAN countries [25].

The scope enables governmental organizations and associated ASEAN Member States to continue to support procedures for human pharmaceuticals placed on the market in ASEAN Member States [26], such as vaccines, antidotes, and other critical or life-saving pharmaceuticals, by facilitating the development of policies, acceptance and acknowledgement arrangements. The scope also covers all operations connected with the development, testing, production, and distribution of pharmaceutical products [27].

In addition to marketed medications, the APRP also works with pharmaceutical products that have not yet been commercialized, particularly those that are utilized in emergency situations, such as vaccines, antidotes, and other critical or life-saving therapies, or medications for specialized access uses [28]. The APRP does not apply to veterinary pharmaceuticals or other healthcare goods that are covered by other ASEAN Agreements, such as medical supplies, herbal remedies, health products, and cosmetics. These principles establish the foundation for an ASEAN National Regulatory Authorities cooperative organization. These ideas would guide the close and organized collaboration arrangements used for planning, executing, and monitoring actions [29][30][31][32].

DISCUSSION

Critical insights into the complexities of pharmaceutical regulatory regimes and their impact on market access and affordability are provided by the comparative analysis of regulatory tactics for generic product approval across Asian nations [33]. The report starts out by recognizing the global importance of generic drugs in lowering healthcare costs and increasing access to necessary medications. It emphasizes the range of regulatory systems, with Asian countries maintaining a more varied and frequently unique regulatory landscape while Europe operates under a centralized framework overseen by the Agency [34][35].

Asian countries, on the other hand, have a more diverse landscape. India, which is renowned for having a thriving pharmaceutical markets having Herbal medicine that numerous conditions, like diabetes, asthma, eczema, premenstrual syndrome, rheumatoid arthritis, Antioxidant, cancer [36][37]. It uses a semi-centralized system that combines strict requirements with quick review times. China places a strong emphasis on regional clinical data, but Japan tends to take a more cautious approach [38]. The variety of regulatory approaches has a direct impact on market access. While Europe's strict regulations guarantee high-quality products, they may cause

product supply to be delayed, which could impede timely patient access [39].

Asian markets, on the other hand, might provide quicker approval but necessitate a nuanced strategy, frequently requiring localization of production and clinical trials. This study highlights the value of flexible tactics and highlights the trade-offs businesses must make in their quest for market penetration [40].

The comparison research also identifies areas where approval procedures may be standardized and harmonised. Global approvals could be expedited by standardizing data requirements and bioequivalence assessment criteria everywhere [41][42]. The reduction of duplication of effort and accelerated market access without compromising safety standards will benefit both the industry and patients. Additionally, it would make it easier for regulatory agencies to work together more closely, which might improve information sharing and mutual recognition of approvals [43][44]. Understanding regulatory methods has a tremendous impact on the larger public health context. However, extra time may unintentionally have an adverse effect on patient health, particularly in emergency medical settings.

CONCLUSION

Significant differences in techniques and their ensuing effects on market access, industry tactics, and public health outcomes have been shown by the comparative analysis of regulatory procedures for generic product approval across Asian nations. However, because of this rigidity, approval times are frequently prolonged. Asian countries, on the other hand, display a more varied environment, with India using a semi-centralized strategy that combines strict standards with quick inspections. China places a strong emphasis on regional clinical data, whereas Japan takes a more cautious approach. With standards potentially delaying patient access, and Asian countries giving quicker approvals with complex localization requirements, this variation affects market accessibility.

To successfully enter new markets, pharmaceutical businesses must adjust their strategy to traverse various regulatory regimes. Asian countries provide quicker approvals but demand a detailed strategy. Opportunities for regional approval processes to be standardized and harmonized become an important factor, with the ability to speed up access to the global market without compromising safety standards. This study also emphasizes the wider public health consequences, highlighting the necessity of a balanced strategy that emphasizes both meticulous analysis and prompt availability to critical treatments. Overall, the conclusions drawn from this analysis offer insightful advice for those involved in the pharmaceutical sector, regulatory bodies, and policy makers who are ultimately working toward the shared objective of enhancing patient access to cost-effective and high-quality generic medications on a global scale.

ACKNOWLEDGEMENT

The authors are thankful to the Principal and Management of Sri Venkateswara College of Pharmacy, Chittoor for providing the necessary infrastructure and facilities to conduct this review work.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

Funding Support

The authors declare that they have no funding for this study.

REFERENCES

[1] Lezotre, P. L. (2013). International cooperation, convergence and harmonization of pharmaceutical regulations: A global perspective. Academic Press. https://doi.org/10.1016/b978-0-12-800053-3.00001-x

[2] Verheugen, G. (2006, September 29). Delivering better information, better access and better prices. Speech presented at the Pharmaceutical Forum, Brussels. Retrieved May 30, 2020, from www.europa.eu

[3] IMS Health. (n.d.). [Internet]. Retrieved May 30, 2020, from www.imshealth.com

[4] European Commission. (2008, April 30). Public-Private Research Initiative to boost the competitiveness of Europe's pharmaceutical industry. [Press release No. IP/08/662]. Retrieved May 30, 2020, from

https://acikbilim.yok.gov.tr/bitstream/handle/20.500.12812/515328/yokAcikBilim_10035869.pdf?sequence=-1

[5] Gambardella, A., Orsenigo, L., & Pammolli, F. (2000, November). Global competitiveness in pharmaceuticals – A European perspective. [Internet]. Report prepared for DG Industry. Retrieved May 30, 2020, from http://ec.europa.eu/enterprise/library/enterprise/papers/pdf/enterprise_paper_01_2001.pdf

[6] Council Directive 89/105/EEC. (1989). Relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. Official Journal of the European Communities, 1989 No. L40/8. Retrieved May 30, 2020, from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A31989L0105

[7] Hancher, L. (2002). The pharmaceuticals market: Competition and free movement actively seeking compromises. In M. McKee, E. Mossialos, & R. Baeten (Eds.), The impact of EU law on health care systems (pp. 235-275). PIE-Peter Lang.

[8] Office of Fair Trading. (2007). The Pharmaceutical Price Regulation Scheme. An OFT Market Study. London: OFT. Retrieved May 30, 2020, from www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf

[9] Hancher, L. (2010). The EU pharmaceuticals market: Parameters and pathways. In E. Mossialos, et al. (Eds.), Health Systems Governance in Europe: The Role of European Union Law and Policy (p. 637). Cambridge University Press.

[10] Commission of the European Communities. (2003, December 30). Communication on parallel import of proprietary medicinal products for which marketing authorisations have already been granted [Internet]. COM (2003) 839 final. Retrieved July 23, 2020, from https://eurex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2003:0839:FIN:en:PDF

[11] Council Regulation 1/2003/EC. (2003). On the implementation of the rules on competition laid down in Articles 81 and 82 of the Treaty. Official Journal of the European Union, 2003 No. L1/1. Retrieved July 25, 2020, from https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32003R0001

[12] Mossialos, E., Baeten, R., Permanand, G., & Hervey, T. K. (Eds.). (2010). Evolution of the European licensing regime from 1965 through to 1988. In Health systems governance in Europe: The role of European Union law and policy (p. 644). Cambridge University Press.

[13] European Parliament and Council Regulation 726/2004/EC. (2004). Laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Official Journal of the European Union, 2004 No. L136/1. Retrieved August 18, 2020, from https://health.ec.europa.eu/system/files/2016-11/reg_2004_726_en_0.pdf

[14] Council Regulation 1768/92/EEC. (1992). Concerning the creation of a supplementary protection certificate for medicinal products. Official Journal of the European Communities, 1992 No. L182/1. Retrieved October 12, 2020, from https://www.legislation.gov.uk/id/eur/1992/1768

[15] Case C-392/97, Farmitalia Carlo Erba. (1999) ECR I-5553. Retrieved October 30, 2020, from https://curia.europa.eu/juris/liste.jsf?language=en&jur=C,T,F&num=C-392/97&td=ALL

[16] PPWG Terms of Reference Article 1 ff. (n.d.). Retrieved October 30, 2020, from https://www.dgra.de/media/pdf/studium/masterthesis/master_laetzel_r.pdf

[17] Zahn. (2001). Developments from ASEAN's ACCSQ Pharmaceutical Product Working Group. Regulatory Affairs Journal, 12-2001, 985-988.

[18] Population Projections Working Group Meeting. (2006). Report item 9, and Annex 12. Retrieved October 30, 2020, from

https://asean.org/events/13-th-pharmaceutical-product-working-group-ppwg-meeting/

[19] Formal ICH Procedure. (2002, October 21). Version published on the ICH. Retrieved November 12, 2020, from http://www.ich.org/cache/compo/276-254-1.html

[20] PPWG Meeting. (2006). Point 19 of the report and Annex 10 contains information a mechanism for the decision-making process and up-dating the Q&A is in preparation. Retrieved November 13, 2020, from https://asean.org/events/13-th-pharmaceutical-product-working-group-ppwg-meeting/

[21] PPWG Meeting. (2005). Retrieved November 14, 2020, from https://asean.org/events/13-th-pharmaceutical-product-working-group-ppwg-meeting/

[22] Principles to CMC Review. (2011). U.S. Department of Public Health, FDA, CDER, Office of Pharmaceutical Science, Manual of Policies and Procedures: Applying ICH Q8 (R2), Q9, and Q10. Retrieved November 15, 2020, from https://www.fda.gov/files/about%20fda/published/Applying-ICH-Q8%28R2%29--Q9--and-Q10-Principles-to-CMC-Review.pdf

[23] Cezanne, J. (2008). Post-approval Management Plan Eyed for all CMC Changes under New Guidance. Validation Times. Retrieved November 16, 2020, from http://findarticles.com/p/articles/mi_hb5677/is_7_10/ai_n32100711/

[24] Arora, T., et al. (2010). Quality by Design for Biotechnology Products—Part 3: Guidance from the Quality by Design Working Group of the PhRMA Biologics and Biotechnology Leadership Committee on how to apply ICH Q8, Q8R1, Q9, and Q10. Biopharm International, 23(1).

[25] Asean Pharmaceutical Regulatory Policy Draft. (2021, August 31). Version. Retrieved November 20, 2020, from https://www.fda.gov.ph/wp-content/uploads/2021/09/ASEAN-PHARMACEUTICAL-REGULATORY-POLICY-1.pdf

[26] Guide to Application for Registration of Medicinal Products. (2012, December). 3rd edition. Department Of Pharmaceutical Services Ministry Of Health Brunei Darussalam.

[27] Guidance on Therapeutic Product Registration In Singapore-Tpb-Gn-005-005. (2019, January). Health Sciences Authority – Health Products Regulation Group, Singapore. Retrieved December 10, 2020, from https://www.hsa.gov.sg/docs/default-source/hprg-tpb/guidances/guidance-on-therapeutic-product-registration-in-singapore_aug22.pdf

[28] A Guideline on Drug Registration Application. (2018, February). Government of the Republic of the Union of Myanmar, Ministry of Health and Sports, Department of Food And Drug Administration, Myanmar. Retrieved December 10, 2020, from https://www.fda.gov.mm/?p=664

[29] Guidance on Drug Approval System of the Philippines. (2016, May). APEC Harmonization Centre, Food and Drug Administration, Philippines. Retrieved December 10, 2020, from https://www.fda.gov.ph/

[30] Guidance on Drug regulation in Thailand. (2017, August). Thai Food and Drug Administration. Retrieved December 10, 2020, from https://nsp.mohw.org.tw/dl-34-960f0775f3234877a9cde3b445548c62.html.

[31] Thai Food and Drug Administration. (2017). Guidance on Drug Regulation in Thailand. Retrieved from https://nsp.mohw.org.tw/dl-34-960f0775f3234877a9cde3b445548c62.html

[32] Lätzel, R. (2007). Development of the ASEAN Pharmaceutical Harmonisation Scheme - An Example of Regional Integration. Retrieved from https://www.dgra.de/media/pdf/studium/masterthesis/master_laetzel_r.pdf

[33] Tongia, A. (n.d.). The Drug Regulatory Landscape in the ASEAN Region. Regulatory Affairs Professionals Society. Retrieved from

https://www.raps.org/news-and-articles/news-articles/2018/1/the-drug-regulatory-landscape-in-the-asean-region

[34] Shweta, H., Vandana, A., Deepak, K., Prafulla, K., & Susanta, K. (2012). A comprehensive study on regulatory requirements for development and filing of generic drugs globally. International Journal of Pharmaceutical Investigation, 2(3), 99-105.

[35] Suzanne, H., & Johnson, K. (2004). Emerging Challenges and Opportunities in Drug Registration and Regulation in Developing Countries. DFID Health Systems Resource Centre. Retrieved from http://heart-resources.org/wp-content/uploads/2012/10/Emerging-challenges-and-opportunities-in-Drug-registration-and-regulation.pdf

[36] Anitha, K., Mohana Lakshmi, S., & Satyanarayana, S. V. (2020). Antidiabetic, lipid lowering and antioxidant potentiating effect of Canavalia species in high fat diet-streptozotocin induced model. Advances in Traditional Medicine, 20, 609-618.

[37] Kuttiappan, A., Lakshmi, S. M., & Satyanarayana, S. V. (2019). Antioxidant potential of ethanolic extract of Canavalia species in high-fat diet and streptozotocin-induced diabetic rats. Pharmacognosy Research, 11(4).

[38] Jain, A., Venkatesh, P. M., Reddy, G. R. M., & Kumar, P. K. T. (2018). Regulatory Requirements & Marketing Authorization of Generic Drugs In Singapore & Thailand. International Journal of Drug Regulatory Affairs, 3(1), 62-74.

[39] Russell, P., et al. (2011). Thailand Regulatory Overview: Life Sciences Handbook. Practical Law Company. Retrieved from http://www.tilleke.com/sites/default/files/2011_PLC_Life_Science_Thailand.pdf

[40] Deep, A., Khurana, G., Kumar, J., & Monga, A. (2019). Comparison of regulatory requirements for registration of pharmaceutical drugs in ASEAN and GCC regions. Applied Clinical Research, Clinical Trials and Regulatory Affairs, 6(1), 62-70.

[41] Wu, Y., Freed, A., Lavrich, D., et al. (2015). Strategies of bringing drug product marketing applications to meet current regulatory standards. AAPS PharmSciTech, 16(4), 986-991.

[42] Lon, C. T., Tsuyuoka, R., Phanouvong, S., et al. (2006). Counterfeit and substandard antimalarial drugs in Cambodia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100(11), 1019-1024.

[43] Latt, N. N., Cho, M. S., Htun, M. M. N., et al. (2016). Healthcare in Myanmar. Nagoya Journal of Medical Science, 78(2), 123-134.

[44] Badjatya, K. J., Bodla, R., & Musyuni, P. (2013). Export registration of pharmaceuticals in Rest Of World countries (ROW). Journal of Drug Delivery and Therapeutics, 3(1), 61-64.